David N. Cook - Feb 28, 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc. (FMTX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Jeannette Potts, as Attorney-in-Fact
Stock symbol
FMTX
Transactions as of
Feb 28, 2022
Transactions value $
$0
Form type
4
Date filed
3/2/2022, 04:14 PM
Previous filing
Feb 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction FMTX Common Stock Award $0 +25K +151.8% $0.00 41.5K Feb 28, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FMTX Stock Option (Right to Buy) Award $0 +37.5K $0.00 37.5K Feb 28, 2022 Common Stock 37.5K $9.86 Direct F2

Explanation of Responses:

Id Content
F1 These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
F2 25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.